胃癌病人唾液胃液血液中CEA定量测定的临床价值

本文作者测定46例胃癌病人唾液、胃液、血液中CEA值，发现唾液、胃液中CEA含量较血液中明显高，有显著性差鼻；唾液、胃液中CEA含量二者间无显著性差异。测定唾液中CEA含量对胃癌诊断尤对术后随访复发有较大临床价值，比测定血液CEA更敏感、方便、无痛苦。     

胃癌病人唾液胃液血清中CEA定量测定的临床价值

本文作者测定４６例胃癌病人唾液、胃液、血液中ＣＥＡ值，发现唾液，胃液中ＣＥＡ含量较血液中明显高，有显著性差异；唾液、胃液中ＣＥＡ含量二者间无显著性差异。测定唾液中ＣＥＡ含量对胃癌诊断尤对术后随访复发有较大临床价值，比测定血液ＣＥＡ更敏感，方便，无痛苦。     

手术前后胃液内癌胚抗原检测在胃癌诊断中的意义

采用放射免疫法测定５１例胃癌、３３例胃良性疾病及８例消化系其它恶性肿瘤患者手术前后胃液内癌胚抗原含量。结果：胃癌组患者胃液内癌胚抗原水平明显高于其它两组，本法对胃癌诊断的敏感性为６８．６％，特异性为８０．５％。作者认为术前检测有助于提高胃癌诊断的正确性，而术后检测对曾行胃大部切除者已无临床意义。     

手术前后胃液内癌胚抗原检测在胃癌诊断中的意义

采用放射免疫法测定51例胃癌、33例胃良性疾病及8例消化系其它恶性肿瘤患者手术前后胃液内癌胚抗原含量。结果：胃癌组患者胃液内癌胚抗原水平明显高于其它两组，本法对胃癌诊断的敏感性为68．6%，特异性为80．5％。作者认为术前检测有助于提高胃癌诊断的正确性，而术后检测对曾行胃大部切除者已无临床意义。     

血清SA,CEA,急性时相蛋白联合检测对结,直肠癌及胃癌的诊断价值

血清ＳＡ、ＣＥＡ、急性时相蛋白联合检测对结、直肠癌及胃癌的诊断价值曾跃红王新华谭亮南自１９９３年１月～１９９５年１２月，对我院普外收住入院的胃癌，结、直肠癌患者各５０例在术前行血清唾液（ＳＡ）、癌胚抗原（ＣＥＡ）、α酸性糖蛋白（α１ＡＧ），α１?..     

血清CEA、CA199、AFP联合检测对肝细胞癌的临床诊断价值

目的 探讨血清癌胚抗原(CEA)、糖类抗原199(CA199)、甲胎蛋白(AFP)联合检测应用于肝细胞癌(以下简称肝癌)的临床诊断价值。方法 选择2020-11—2021-11郑州大学第一附属医院收治的128例肝占位患者的临床和病理资料。病理结果为肝癌41例,良性占位病变87例。以病理结果为“金标准”;以CEA≥5 ng/mL、CA199≥37 U/mL、AFP≥10 ng/mL作为临界值。评价血清CEA、CA199、AFP联合检测用于肝癌的临床诊断价值。结果 肝癌患者的血清CEA、CA199、AFP水平均显著高于良性占位患者,差异均有统计学意义(P<0.05)。血清CEA、CA199、AFP联合检测诊断肝癌的敏感性、特异性、准确率,以及阳性预测值、阴性预测值均显著高于3个单项检测,差异均有统计学意义(P<0.05)。结论 血清CEA、CA199、AFP联合检测对肝癌的诊断有较高的敏感性、特异性、准确率,以及阳性预测值和阴性预测值,可作为肝占位病变的重要定性诊断方法和对肝癌高危人群的筛查手段。但仍需进行超声、CT、MRI,以及PET-CT等影像学检查,以确定肝癌的部位、大小...     

胃液α1-抗胰蛋白酶、CEA、Ca199和Ca724检测在胃癌诊断中的价值

探讨胃液中α1-抗胰蛋白酶、CEA、Ca199、Ca724的检测在胃癌诊断中的价值。选取2011年2月—2013年4月行胃镜检查的67例胃癌患者(胃癌组)、43例胃部良性疾病患者(胃良性疾病组)和25例健康人(对照组)为研究对象,测定3组患者胃液中的α1-抗胰蛋白酶、CEA、Ca199、Ca724的水平,进行统计学分析比较。胃癌组胃液中α1-抗胰蛋白酶、CEA、Ca199、Ca724的浓度显著高于胃部良性疾病组和对照组,且差异有统计学意义(P0.05)。胃液α1-抗胰蛋白酶检测胃癌的敏感度、特异度和准确率分别为92.5%、89.7%和91.1%,均明显高于CEA、Ca199、Ca724的敏感度、特异度和准确率(P0.05)。与胃液CEA、Ca199、Ca724测定相比,胃液α1-抗胰蛋白酶是诊断胃癌敏感且特异的标志物,有助于提高胃癌诊断的准确率,值得进一步研究及探讨。     

胃癌病人胃液中光散射颗粒的结构与组成研究

通过对108例胃癌病人及50例非胃癌病人进行胃的光散射研究,结果发现胃癌病人胃液有明显的光散射,其强度比非胃癌病人胃液光散射强度大6～8倍,针对胃癌病人胃液光散射增强的机制,应用电镜观察发现胃癌病人胃液中的特征散射颗粒较非胃癌病人胃液中的特征散射颗粒多约6～8倍,进一步研究了胃癌胃液中光散射系该颗粒提供,通过物理及化学方法对该颗粒的组成进行了研究,实验证明,这些颗粒是由磷脂组成,其结构可能是具有双层磷脂膜结构的脂质体,此研究对胃癌的代谢及新的诊断方法提供了依据。     

肿瘤标志物TSGF及CEA对肿瘤的诊断价值探讨

目的 比较恶性瘤特异性生长因子（TSGF）和癌胚抗原（CEA）在肿瘤诊断中的价值。方法 将患者分成恶性肿瘤组和非恶性肿瘤组两组,非恶性肿瘤又可分为炎症组和非炎症组;检测各组血清TSGF及CEA水平。结果 TSGF和CEA在恶性肿瘤、非恶性肿瘤、炎症及非炎症组中的阳性检出率分别为67．41％和38．84％、24．56％和2．63％、32．35％和5．88％及18．25％和0％,二者在恶性肿瘤组中的阳性率明显高于其它组（P＜0．005）;在恶性肿瘤组中,TS－GF的阳性率高于CEA（P＜0．005）。结论 血清TSGF的检测为我们提供了一个较好的肿瘤检测手段,它具有敏感性高及广谱性的优点。CEA对肿瘤检测的特异性较TSGF高。两者联合检测可提高肿瘤的诊断率。     

CRP联合AFP、CEA对原发性肝癌早期诊断及病情判断的临床价值

目的探讨C-反应蛋白（C-reactive protein,CRP）联合甲胎蛋白（AFP）、癌胚抗原（CEA）在肝癌诊断及病情判断中的临床价值。方法随机检测健康体检、肝良性疾病、肝脏癌患者的血清标本各60例。应用散射免疫比浊法检测CRP血清水平;电化学发光法检测AFP、CEA血清水平。结果肝癌组CRP、AFP、CEA血清水平明显高于肝良性疾病组和健康体检组,差异有统计学意义（均P〈0.05）;CRP、AFP、CEA在肝癌组的阳性检出率明显高于肝脏良性疾病及正常体检组（均P〈0.05）;血清CRP水平随着肝癌临床病理分期加深而增加,差异有统计学意义（P〈0.05）;而血清AFP及CEA水平与各临床病理分期却无明显的相关性。结论在对疑似肝癌或肝癌高危人群进行筛查时,可以考虑将CRP设为检查项目之一,同时与肝癌生化标志物AFP、CEA联合检测,优势互补,以期发现早期肝癌病例。并且,CRP与肝癌不同的临床病理分期有一定的关联,可能较早的对病情的恶性程度做出判断。     

比较GP73和AFP联合检测与AFP单项检测对原发性肝癌的诊断价值的meta分析

目的探讨血清标志物GP73和AFP联合检测在原发性肝癌中的诊断价值。方法通过计算机及手工查阅获得联合检测血清GP73和AFP来诊断原发性肝癌的文献,按纳入与排除标准筛选文献、提取数据,采用MetaDisc 1.4软件检验研究间的异质性,对诊断准确度指标进行Meta分析,绘制综合受试者工作特征曲线。结果从145篇文献中筛选出12篇符合纳入标准的研究。异质性检验提示GP73和AFP联合不存在阈值效应,但存在其他原因导致的异质性,采用随机效应模型做Meta分析。结果显示:GP73和AFP联合检测和AFP单项检测诊断原发性肝癌的汇总灵敏度、特异度分别为0.889、0.831;0.617、0.835。两者的综合受试者工作特征曲线下面积分别为0.9282、0.7845,Q指数分别为0.8629、0.7225。结论 GP73和AFP联合检测可以明显提高诊断灵敏度,其对肝癌的诊断敏感性可达到88.9%,而特异度保持在较高水平(83.1%),弥补了AFP的不足,提高了原发性肝癌的诊断率。     

Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer

The early diagnosis of pancreatic carcinoma is essential for increasing patient survival rates. In this study, 52 patients with suspected pancreatic diseases were examined to investigate the value of K-ras codon 12 point mutation, levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9), and cytology of pancreatic juice in the diagnosis of pancreatic carcinoma. Pancreatic juice was taken without secretin stimulation. K-ras mutation was detected by enriched polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP). K-ras mutation in pancreatic juice was more frequent in carcinoma than in benign diseases (P = 0.0448). The positive predictive value of K-ras mutation for the diagnosis of neoplastic disease was 83%. The CEA level in pancreatic juice in carcinoma was significantly greater than that in benign disease (P < 0.0001). When the cutoff level of CEA was set at 50 ng/ml, its accuracy for the diagnosis of carcinoma was 85%. A multivariate analysis showed that K-ras mutation and CEA level in pancreatic juice, as well as serum CA19-9 level and age of the patient were independent variables for the diagnosis of carcinoma, and the accuracy of diagnosis by this analysis was increased to 90%. In conclusion, both K-ras mutation and CEA level in pancreatic juice may be valuable for the diagnosis of carcinoma. Better discrimination was possible with a multivariate analysis. Received for publication on Dec. 12, 1998; accepted on July 19, 1999     

Immunoreactive carcinoembryonic antigen in gastric juice in patients with gastric cancer

To clarify the significance of immunoreactive carcinoembryonic antigen in gastric juice (gastric CEA) from gastric cancer patients, we studied the gastric CEA in comparison with cancer progress, histologic types of tumors, staining, for CEA and extent of intestinal metaplasia. The gastric CEA levels from patients with other gastric diseases, i.e., gastric ulcer, duodenal ulcer and chronic gastritis were also investigated. The mean gastric CEA level from gastric cancer patients was significantly higher than from gastric or duodenal ulcer patients, but there was no significant difference between levels in patients with gastric cancer and in those with chronic gastritis. The gastric CEA levels from cancer patients increased with progression of the cancer. The differentiated carcinomas showed significantly higher gastric CEA levels than the poorly differentiated carcinomas. Positive CEA tumors showed significantly higher gastric CEA levels than did the negative CEA tumors. The tumors with diffuse intestinal metaplasia revealed high gastric CEA levels. Determination of gastric CEA levels is considered to be useful for screening of gastric cancer.     

肿瘤标志物在胃癌患者中的诊断及预后价值

目的 探讨肿瘤标志物CEA、CA19-9、CA72-4及CA242在胃癌诊断及预后判断中的应用价值.方法 回顾性分析2002-2007年间在北京肿瘤医院就诊的160例胃癌患者血清肿瘤标志物、临床病理参数以及预后资料.结果 160例胃癌患者中CEA、CA19-9、CA72-4及CA242的初诊阳性率分别为37.7％、26.7％、37.6％及21.3％,4种标志物联合检测阳性率为62.9％.CEA阳性与淋巴结转移有关（P=0.029）;CA72-4阳性与脉管浸润及Ⅲ、Ⅳ期胃癌有关（P=0.039,P=0.011）.CA19-9阳性和阴性患者中位生存期分别为17.0和32.0个月,CA72-4阳性和阴性患者中位生存期分别为14.8和37.5个月,差异有统计学意义（P＜0.01）.多因素生存分析提示,CA72-4可以作为独立预后因子（P=0.012）,CA72-4阳性患者的死亡危险系数是阴性患者的2.147倍.结论 肿瘤标志物CEA、CA19-9、CA72-4及CA242在胃癌患者的诊断和预后判断中有重要价值,联合检测可提高阳性率;其中CA72-4可以作为独立预后因子,CA19-9及CA72-4与胃癌患者预后相关.     

The clinical usefulness of preoperative CEA determination in gastric cancer

Between 1980 and 1984, preoperative serum carcinoembryonic antigen (CEA) was determined in 468 patients with gastric cancer to evaluate its clinical usefulness. The positive rate of preoperative CEA was 20.9 per cent in these 468 patients. A significantly higher CEA positive rate was obtained in those patients with liver metastasis (69.2 per cent), n_3–4 (40.0 per cent), stage IV gastric cancer (37.0 per cent) and Pap, Tub₁ histological type (26.3 per cent) (p<0.01). It is interesting that the positive rate of the 49 unresectable patients was 51.0 per cent, which was significantly higher than 17.4 per cent of the 419 resectable cases (p<0.01). CEA levels in 16 of the 39 patients with liver metastasis were more than 100 ng/ml. In contrast, serosal invasion and peritoneal metastasis were less correlated to the CEA positive rate. In the 419 resected cases, the 5 year survival rate in the higher CEA group of more than 50 ng/ml (35 cases) was 4.4 per cent, which was significantly lower than 64.0 per cent in the negative group (346 cases) (p<0.01). These results show that CEA determination in patients with gastric cancer is useful for the prediction of prognosis, as well as for a diagnostic tool to discover the presence of liver or lymph node metastasis.     

The clinical usefulness of preoperative CEA determination in gastric cancer

Between 1980 and 1984, preoperative serum carcinoembryonic antigen (CEA) was determined in 468 patients with gastric cancer to evaluate its clinical usefulness. The positive rate of preoperative CEA was 20.9 per cent in these 468 patients. A significantly higher CEA positive rate was obtained in those patients with liver metastasis (69.2 per cent), n3-4 (40.0 per cent), stage IV gastric cancer (37.0 per cent) and Pap, Tub1 histological type (26.3 per cent) (p less than 0.01). It is interesting that the positive rate of the 49 unresectable patients was 51.0 per cent, which was significantly higher than 17.4 per cent of the 419 resectable cases (p less than 0.01). CEA levels in 16 of the 39 patients with liver metastasis were more than 100 ng/ml. In contrast, serosal invasion and peritoneal metastasis were less correlated to the CEA positive rate. In the 419 resected cases, the 5 year survival rate in the higher CEA group of more than 50 ng/ml (35 cases) was 4.4 per cent, which was significantly lower than 64.0 per cent in the negative group (346 cases) (p less than 0.01). These results show that CEA determination in patients with gastric cancer is useful for the prediction of prognosis, as well as for a diagnostic tool to discover the presence of liver or lymph node metastasis.     

Further investigations of immunoreactive carcinoembryonic antigen (CEA) in colorectal cancer patients with particular emphasis on the correlation between immunoreactive CEA levels in tissue,feces and blood

Immunoreactive carcinoembryonic antigen (IR-CEA) levels in colorectal cancer and mucosal tissues, feces and blood were measured in 14 colorectal cancer patients to study the correlation. IR-CEA levels in colorectal cancer tissues were about 30 times higher than those in colonic mucosal tissues. The correlation coefficient between IR-CEA levels in the tumor tissue and serum was 0.654 (p<0.02). We assumed that the total tumor IR-CEA levels were the product of the tumor IR-CEA level, by the estimated tumor weight. The correlation coefficient between the serum IR-CEA level and total tumor IR-CEA level was 0.750 (p<0.001). When the patients were divided into two groups with more and less a total tumor IR-CEA level of 65,000 ng, respectively, the statistical difference in serum IR-CEA levels was p<0.001. The differences in fecal IR-CEA levels between these two groups, however, are statistically insignificant (p<0.3). We assumed that there was a positive correlation between the IR-CEA levels in blood and tumor from the consideration that circulating IR-CEA orginates from the metabolic imbalance of its production in colorectal cancer tissues over its degradation in the liver. Moreover, it is essential to consider that the fecal IR-CEA levels may be influenced by the following three factors: the intraluminal direct release of CEA from tumor, no degradation process of CEA in the gut lumen, and the intraluminal transport rate of colonic contents.     

CT联合血清CEA、CA19-9检测对胰腺癌诊断价值分析

目的:探讨CT联合血清癌胚抗原(CEA)、糖链抗原(CA19-9)检测在胰腺癌诊断中的意义.方法:回顾性分析35例经手术病理证实的胰腺癌患者,对CT及血清CEA、CA19-9检查结果进行比较,分析CT联合血清CEA、CA19～9检测对胰腺癌的诊断价值.结果:联合检测的确诊率明显高于CT影像检查、血清肿瘤标志物CEA、CA19-9单独检测,联合检测与各单项检测之间比较差异均有统计学意义(P＜0.05).结论:CT影像联合血清肿瘤标志物CEA、CA19-9检测有助于胰腺癌的临床诊断.     

The clinical value of tissue carcinoembryonic antigen in breast cancer

The relationship of tissue carcinoembryonic antigen (CEA) to clinicopathological factors and prognosis was investigated in 168 patients with invasive ductal carcinoma of the breast. Tissue CEA was determined by radioimmunoassay and a level of 5.1 ng/ml or more considered to be positive. Tissue CEA was positive in 31.5 per cent of the patients overall and, of the clinicopathological factors, tumor size and the presence or absence of lymph node involvement were not found to be correlated with tissue CEA. However, the tissue CEA positivity rate was significantly higher in patients who had four or more metastatic lymph nodes (p<0.01). Tissue CEA-positive patients showed earlier recurrence than CEA-negative patients (p<0.01) and had a poorer outcome (p<0.05). Thus, tissue CEA is considered useful as a prognostic index for primary breast cancer patients.